• Recruiting

NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis

NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

EMN 22 DARA AMYLOIDOSIS

NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis


This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.


Sponsor

European Myeloma Network


Collaborator

Janssen Pharmaceutical

 

ClinicalTrials.gov Identifier: NCT04131309

Official Title: Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

First Posted : October 18, 2019

Click here to see details on ClinicalTrials.gov


EMN22 - European Myeloma Network (myeloma-europe.org)

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute

Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information


Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Drug: Daratumumab

Drug: Bortezomib Injection

Drug: Dexamethasone oral tablet

 

Locations

Europe

France

Greece

Italy

Netherlands


Posts Archive